Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
December 19, 2019 13:44 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
December 18, 2019 09:05 ET
|
Onconova Therapeutics, Inc.
Proceeds provide sufficient funds to extend operations and ongoing trials late into the fourth quarter of 2020Company does not intend to raise additional capital for ninety days following the closing...
Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil
December 17, 2019 07:30 ET
|
Onconova Therapeutics, Inc.; Pint Pharma
The INSPIRE Trial enters the final stage of enrollment after surpassing 90% of the required number of randomized patients in November 2019 Pint Pharma Facilitates Opening of Phase 3 INSPIRE Trial in...
Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
December 10, 2019 15:07 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
December 09, 2019 09:00 ET
|
Onconova Therapeutics, Inc.
Genomic Profiling at Study Entry in Patients with Higher Risk Myelodysplastic Syndrome (HR-MDS) Following Hypomethylating (HMA) Failure: Results From the INSPIRE Trial, including RAS and other...
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
December 09, 2019 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
December 06, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
November 25, 2019 09:26 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering
November 21, 2019 11:23 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada
November 21, 2019 10:16 ET
|
Onconova Therapeutics, Inc.
Knight receives exclusive license to commercialize rigosertib in CanadaOnconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit...